Mayzent

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Siponimod фумаровая kiselina

Available from:

Novartis Europharm Limited 

ATC code:

L04

INN (International Name):

siponimod

Therapeutic group:

Selektivni imunosupresivi

Therapeutic area:

Multipla Skleroza, Рецидивно-Ремиттирующее

Therapeutic indications:

Mayzent indiciran za liječenje odraslih bolesnika sa sekundarno-прогрессирующим multiplom sklerozom (ВПРС) s aktivnim bolesti svjedoče recidiva ili značajke za vizualizaciju aktivnosti upalnog procesa.

Product summary:

Revision: 10

Authorization status:

odobren

Authorization date:

2020-01-13

Patient Information leaflet

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo
otkrivanje novih sigurnosnih
informacija. Od zdravstvenih radnika se traži da prijave svaku sumnju
na nuspojavu za ovaj lijek. Za
postupak prijavljivanja nuspojava vidjeti dio 4.8.
1.
NAZIV LIJEKA
Mayzent 0,25 mg filmom obložene tablete
Mayzent 1 mg filmom obložene tablete
Mayzent 2 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Mayzent 0,25 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 0,25 mg siponimoda u obliku
siponimod fumaratne kiseline.
_Pomoćna tvar s poznatim učinkom _
Jedna tableta sadrži 59,1 mg laktoze (u obliku laktoze hidrata) i
0,092 mg sojinog lecitina.
Mayzent 1 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 1 mg siponimoda u obliku
siponimod fumaratne kiseline.
_Pomoćna tvar s poznatim učinkom _
Jedna tableta sadrži 58,3 mg laktoze (u obliku laktoze hidrata) i
0,092 mg sojinog lecitina.
Mayzent 2 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 2 mg siponimoda u obliku
siponimod fumaratne kiseline.
_Pomoćna tvar s poznatim učinkom _
Jedna tableta sadrži 57,3 mg laktoze (u obliku laktoze hidrata) i
0,092 mg sojinog lecitina.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta
Mayzent 0,25 mg filmom obložene tablete
Blijedo crvena, okrugla, bikonveksna filmom obložena tableta s
ukošenim rubom, promjera približno
6,1 mm, s logotipom tvrtke s jedne strane i oznakom „T“ s druge
strane.
Mayzent 1 mg filmom obložene tablete
Ljubičastobijela, okrugla, bikonveksna filmom obložena tableta s
ukošenim rubom, promjera približno
6,1 mm, s logotipom tvrtke s jedne strane i oznakom „L“ s druge
strane.
Mayzent 2 mg filmom obložene tablete
Blijedo žuta, okrugla, bikonveksna filmom obložena tableta s
ukošenim rubom, promjera približno
6,1 mm, s logotipom tvrtke s jedne strane i oznakom „II“ s druge
strane.
3
4.
KLINIČKI PODACI
4.1
TERAPIJSKE IND
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo
otkrivanje novih sigurnosnih
informacija. Od zdravstvenih radnika se traži da prijave svaku sumnju
na nuspojavu za ovaj lijek. Za
postupak prijavljivanja nuspojava vidjeti dio 4.8.
1.
NAZIV LIJEKA
Mayzent 0,25 mg filmom obložene tablete
Mayzent 1 mg filmom obložene tablete
Mayzent 2 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Mayzent 0,25 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 0,25 mg siponimoda u obliku
siponimod fumaratne kiseline.
_Pomoćna tvar s poznatim učinkom _
Jedna tableta sadrži 59,1 mg laktoze (u obliku laktoze hidrata) i
0,092 mg sojinog lecitina.
Mayzent 1 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 1 mg siponimoda u obliku
siponimod fumaratne kiseline.
_Pomoćna tvar s poznatim učinkom _
Jedna tableta sadrži 58,3 mg laktoze (u obliku laktoze hidrata) i
0,092 mg sojinog lecitina.
Mayzent 2 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 2 mg siponimoda u obliku
siponimod fumaratne kiseline.
_Pomoćna tvar s poznatim učinkom _
Jedna tableta sadrži 57,3 mg laktoze (u obliku laktoze hidrata) i
0,092 mg sojinog lecitina.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta
Mayzent 0,25 mg filmom obložene tablete
Blijedo crvena, okrugla, bikonveksna filmom obložena tableta s
ukošenim rubom, promjera približno
6,1 mm, s logotipom tvrtke s jedne strane i oznakom „T“ s druge
strane.
Mayzent 1 mg filmom obložene tablete
Ljubičastobijela, okrugla, bikonveksna filmom obložena tableta s
ukošenim rubom, promjera približno
6,1 mm, s logotipom tvrtke s jedne strane i oznakom „L“ s druge
strane.
Mayzent 2 mg filmom obložene tablete
Blijedo žuta, okrugla, bikonveksna filmom obložena tableta s
ukošenim rubom, promjera približno
6,1 mm, s logotipom tvrtke s jedne strane i oznakom „II“ s druge
strane.
3
4.
KLINIČKI PODACI
4.1
TERAPIJSKE IND
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-01-2024
Public Assessment Report Public Assessment Report Bulgarian 23-01-2020
Patient Information leaflet Patient Information leaflet Spanish 16-01-2024
Public Assessment Report Public Assessment Report Spanish 23-01-2020
Patient Information leaflet Patient Information leaflet Czech 16-01-2024
Public Assessment Report Public Assessment Report Czech 23-01-2020
Patient Information leaflet Patient Information leaflet Danish 16-01-2024
Public Assessment Report Public Assessment Report Danish 23-01-2020
Patient Information leaflet Patient Information leaflet German 16-01-2024
Public Assessment Report Public Assessment Report German 23-01-2020
Patient Information leaflet Patient Information leaflet Estonian 16-01-2024
Public Assessment Report Public Assessment Report Estonian 23-01-2020
Patient Information leaflet Patient Information leaflet Greek 16-01-2024
Public Assessment Report Public Assessment Report Greek 23-01-2020
Patient Information leaflet Patient Information leaflet English 16-01-2024
Public Assessment Report Public Assessment Report English 23-01-2020
Patient Information leaflet Patient Information leaflet French 16-01-2024
Public Assessment Report Public Assessment Report French 23-01-2020
Patient Information leaflet Patient Information leaflet Italian 16-01-2024
Public Assessment Report Public Assessment Report Italian 23-01-2020
Patient Information leaflet Patient Information leaflet Latvian 16-01-2024
Public Assessment Report Public Assessment Report Latvian 23-01-2020
Patient Information leaflet Patient Information leaflet Lithuanian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-01-2024
Public Assessment Report Public Assessment Report Lithuanian 23-01-2020
Patient Information leaflet Patient Information leaflet Hungarian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 16-01-2024
Public Assessment Report Public Assessment Report Hungarian 23-01-2020
Patient Information leaflet Patient Information leaflet Maltese 16-01-2024
Public Assessment Report Public Assessment Report Maltese 23-01-2020
Patient Information leaflet Patient Information leaflet Dutch 16-01-2024
Public Assessment Report Public Assessment Report Dutch 23-01-2020
Patient Information leaflet Patient Information leaflet Polish 16-01-2024
Public Assessment Report Public Assessment Report Polish 23-01-2020
Patient Information leaflet Patient Information leaflet Portuguese 16-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 16-01-2024
Public Assessment Report Public Assessment Report Portuguese 23-01-2020
Patient Information leaflet Patient Information leaflet Romanian 16-01-2024
Public Assessment Report Public Assessment Report Romanian 23-01-2020
Patient Information leaflet Patient Information leaflet Slovak 16-01-2024
Public Assessment Report Public Assessment Report Slovak 23-01-2020
Patient Information leaflet Patient Information leaflet Slovenian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 16-01-2024
Public Assessment Report Public Assessment Report Slovenian 23-01-2020
Patient Information leaflet Patient Information leaflet Finnish 16-01-2024
Public Assessment Report Public Assessment Report Finnish 23-01-2020
Patient Information leaflet Patient Information leaflet Swedish 16-01-2024
Public Assessment Report Public Assessment Report Swedish 23-01-2020
Patient Information leaflet Patient Information leaflet Norwegian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 16-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 16-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 16-01-2024

Search alerts related to this product

View documents history